Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685870 | 0.93 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2683977 | 0.92 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2686083 | 0.92 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2688070 | 0.92 | BCAT2 (0.49) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2685314 | 0.88 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2687840 | 0.87 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2684378 | 0.85 | TRPV1 (0.61) | NPC1RAB9ASMN1; SMN2TRPV1TP53 | |
| SCHEMBL2687034 | 0.79 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2TRPV1KCNQ3 | |
| SCHEMBL2686986 | 0.79 | TRPV1 (0.55) | NPC1RAB9ASMN1; SMN2TRPV1NAMPT | |
| SCHEMBL6109278 | 0.77 | TRPV1 (0.59) | NPC1RAB9ASMN1; SMN2TRPV1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | NPC1 936/4885RAB9A 2003/4885SMN1; SMN2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.